It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- A clinical-stage global gene therapy company focused on developing curative therapies for people with rare diseases
- Lead asset Libmeldy (OTL-200) = a gene therapy nearing the regulatory evaluation phase in the U.S for metachromatic leukodystrophy (MLD)